Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 7 | 2021 | 495 | 1.920 |
Why?
|
| Drug Prescriptions | 2 | 2021 | 188 | 1.210 |
Why?
|
| Emergency Service, Hospital | 4 | 2021 | 1020 | 1.190 |
Why?
|
| Drug Overdose | 3 | 2018 | 120 | 0.910 |
Why?
|
| Physostigmine | 1 | 2022 | 4 | 0.850 |
Why?
|
| Prescription Drug Monitoring Programs | 2 | 2021 | 2 | 0.800 |
Why?
|
| Delirium | 1 | 2022 | 56 | 0.790 |
Why?
|
| Prescription Drug Misuse | 2 | 2018 | 22 | 0.750 |
Why?
|
| Hospitals, Urban | 1 | 2021 | 44 | 0.740 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 102 | 0.710 |
Why?
|
| Hospitals, Rural | 1 | 2020 | 21 | 0.680 |
Why?
|
| Poisoning | 1 | 2020 | 29 | 0.680 |
Why?
|
| Opioid-Related Disorders | 3 | 2020 | 465 | 0.580 |
Why?
|
| Information Dissemination | 1 | 2018 | 117 | 0.570 |
Why?
|
| Oxycodone | 2 | 2014 | 32 | 0.560 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 713 | 0.510 |
Why?
|
| Pharmaceutical Preparations | 1 | 2017 | 121 | 0.500 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 151 | 0.480 |
Why?
|
| Toxicology | 1 | 2014 | 34 | 0.460 |
Why?
|
| Oxymorphone | 1 | 2013 | 6 | 0.440 |
Why?
|
| Emergency Medicine | 3 | 2021 | 185 | 0.410 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2013 | 47 | 0.410 |
Why?
|
| Massachusetts | 4 | 2021 | 2086 | 0.320 |
Why?
|
| Faculty, Medical | 3 | 2021 | 203 | 0.320 |
Why?
|
| Fentanyl | 2 | 2020 | 70 | 0.310 |
Why?
|
| Humans | 21 | 2024 | 59343 | 0.250 |
Why?
|
| Prealbumin | 1 | 2024 | 20 | 0.240 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2024 | 17 | 0.230 |
Why?
|
| Female | 12 | 2024 | 30847 | 0.220 |
Why?
|
| Retrospective Studies | 6 | 2021 | 5981 | 0.220 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2023 | 7 | 0.220 |
Why?
|
| Renin-Angiotensin System | 1 | 2023 | 22 | 0.210 |
Why?
|
| Rivastigmine | 1 | 2022 | 2 | 0.210 |
Why?
|
| Acetylcholinesterase | 1 | 2022 | 16 | 0.210 |
Why?
|
| Vasodilator Agents | 1 | 2023 | 60 | 0.210 |
Why?
|
| Cardiomyopathies | 1 | 2024 | 119 | 0.210 |
Why?
|
| Muscarinic Antagonists | 1 | 2022 | 26 | 0.210 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2022 | 44 | 0.200 |
Why?
|
| Research Support as Topic | 2 | 2019 | 44 | 0.200 |
Why?
|
| Middle Aged | 8 | 2024 | 16242 | 0.200 |
Why?
|
| Amnesia | 2 | 2020 | 11 | 0.200 |
Why?
|
| Physicians, Women | 1 | 2021 | 42 | 0.190 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 18 | 0.180 |
Why?
|
| Uganda | 1 | 2020 | 34 | 0.170 |
Why?
|
| Forecasting | 1 | 2021 | 221 | 0.170 |
Why?
|
| Male | 10 | 2024 | 27505 | 0.170 |
Why?
|
| Financing, Government | 1 | 2019 | 33 | 0.170 |
Why?
|
| Prescription Drugs | 1 | 2019 | 50 | 0.160 |
Why?
|
| Adult | 8 | 2023 | 15745 | 0.160 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2018 | 29 | 0.160 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 5079 | 0.160 |
Why?
|
| RNA, Small Interfering | 1 | 2024 | 851 | 0.150 |
Why?
|
| Efficiency | 1 | 2018 | 41 | 0.150 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2020 | 117 | 0.150 |
Why?
|
| Hospitals, Community | 1 | 2018 | 71 | 0.150 |
Why?
|
| Writing | 1 | 2018 | 43 | 0.150 |
Why?
|
| Rural Population | 1 | 2020 | 191 | 0.150 |
Why?
|
| Drug Approval | 1 | 2017 | 27 | 0.140 |
Why?
|
| Morbidity | 1 | 2017 | 106 | 0.130 |
Why?
|
| Insufflation | 2 | 2013 | 10 | 0.130 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 95 | 0.130 |
Why?
|
| Infant | 1 | 2020 | 1527 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2021 | 2437 | 0.120 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2014 | 6 | 0.120 |
Why?
|
| Codeine | 1 | 2014 | 6 | 0.120 |
Why?
|
| Tonsillectomy | 1 | 2014 | 9 | 0.120 |
Why?
|
| Aged | 5 | 2024 | 13308 | 0.120 |
Why?
|
| Child, Preschool | 1 | 2020 | 1838 | 0.120 |
Why?
|
| Adolescent | 3 | 2021 | 5921 | 0.120 |
Why?
|
| Women's Health | 1 | 2017 | 390 | 0.110 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 93 | 0.110 |
Why?
|
| Receptors, Opioid, mu | 1 | 2013 | 15 | 0.110 |
Why?
|
| Universities | 1 | 2014 | 152 | 0.110 |
Why?
|
| Minocycline | 1 | 2012 | 25 | 0.100 |
Why?
|
| Nasopharynx | 1 | 2012 | 21 | 0.100 |
Why?
|
| Acetaminophen | 1 | 2012 | 52 | 0.100 |
Why?
|
| Skin Diseases | 1 | 2012 | 74 | 0.100 |
Why?
|
| Child | 3 | 2019 | 4301 | 0.090 |
Why?
|
| Young Adult | 1 | 2021 | 4324 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2024 | 5145 | 0.090 |
Why?
|
| Vertebral Artery | 1 | 2010 | 27 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 898 | 0.090 |
Why?
|
| Emergency Medical Services | 1 | 2013 | 249 | 0.080 |
Why?
|
| Internet | 1 | 2013 | 458 | 0.080 |
Why?
|
| Academic Medical Centers | 2 | 2021 | 314 | 0.080 |
Why?
|
| United States | 2 | 2019 | 7499 | 0.070 |
Why?
|
| Walk Test | 1 | 2024 | 7 | 0.060 |
Why?
|
| RNAi Therapeutics | 1 | 2024 | 12 | 0.060 |
Why?
|
| Injections, Subcutaneous | 1 | 2024 | 70 | 0.060 |
Why?
|
| Angiotensins | 1 | 2023 | 5 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2024 | 387 | 0.050 |
Why?
|
| Angiotensin II | 1 | 2023 | 24 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2023 | 170 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2024 | 680 | 0.050 |
Why?
|
| Oligopeptides | 1 | 2023 | 134 | 0.050 |
Why?
|
| Hypoxia | 1 | 2023 | 107 | 0.050 |
Why?
|
| Ligands | 1 | 2023 | 422 | 0.050 |
Why?
|
| Career Mobility | 1 | 2021 | 62 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2020 | 187 | 0.040 |
Why?
|
| Syndrome | 1 | 2020 | 172 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2019 | 22 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 665 | 0.040 |
Why?
|
| Leadership | 1 | 2021 | 201 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2019 | 113 | 0.040 |
Why?
|
| Hippocampus | 1 | 2020 | 238 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2019 | 120 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 672 | 0.040 |
Why?
|
| Mentors | 1 | 2018 | 117 | 0.040 |
Why?
|
| Quality of Life | 1 | 2024 | 1114 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2019 | 250 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 959 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1232 | 0.030 |
Why?
|
| Acute Disease | 1 | 2018 | 658 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1225 | 0.030 |
Why?
|
| Social Support | 1 | 2018 | 358 | 0.030 |
Why?
|
| Analgesics | 1 | 2016 | 99 | 0.030 |
Why?
|
| Pain Management | 1 | 2016 | 144 | 0.030 |
Why?
|
| Acne Vulgaris | 1 | 2012 | 24 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2012 | 140 | 0.020 |
Why?
|
| Necrosis | 1 | 2012 | 138 | 0.020 |
Why?
|
| Parkinson Disease | 1 | 2012 | 97 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 5001 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 2036 | 0.010 |
Why?
|